A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
AstraZeneca
Study ID
NCT07391657
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Relapsed Refractory Multiple Myeloma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AZD0120 — BIOLOGICAL
    CAR-T Cells
  • Daratumumab — DRUG
    Daratumumab
  • Carfilzomib — DRUG
    Carfilzomib
  • Dexamethasone — DRUG
    Dexamethasone
  • Bortezomib — DRUG
    Bortezomib
  • Pomalidomide — DRUG
    Pomalidomides

Study Details

This is a randomised, multicentre, controlled, open-label, Phase III global study comparing the efficacy and safety of AZD0120 versus standard regimens (DKd \[daratumumab, carfilzomib, and dexamethasone\], DPd \[daratumumab, pomalidomide, and dexamethasone\], PVd \[pomalidomide, bortezomib and dexamethasone\], or Kd \[carfilzomib and dexamethasone\]) in participants with RRMM.

Key Dates

Start date
Feb 23, 2026
Status verified
Jun 2026
Primary completion
Jun 14, 2028
Completion
Jul 29, 2030

Study Design

Enrollment
508 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A
    AZD0120
  • Active Comparator: Arm B
    1 of the following 4 standard regimens per investigator choice; DKd, DPd, PVd, Kd.

Primary Outcome Measure

To demonstrate the superiority of AZD0120 relative to standard therapy (DKd, DPd, PVd, or Kd) by assessment of PFS in participants with RRMM. [ Time Frame: 3 years ]

Central Contacts

Locations (48)

FacilityCityStateZIPSite coordinators
Research SiteGilbertArizona85234-
Research SitePhoenixArizona85054-
Research SiteTucsonArizona85719-
Research SiteLa JollaCalifornia92093-
Research SiteSacramentoCalifornia95817-
Research SiteSanta MonicaCalifornia90404-
Research SiteDenverColorado80218-
Research SiteNew HavenConnecticut06510-
Research SiteWashington D.C.District of Columbia20007-
Research SiteCoral GablesFlorida33156-
Research SiteTampaFlorida33606-
Research SiteAtlantaGeorgia30322-
Research SiteChicagoIllinois60612-
Research SitePark RidgeIllinois60068-
Research SiteIowa CityIowa52242-
Research SiteKansas CityKansas66160-
Research SiteLouisvilleKentucky40207-
Research SiteBostonMassachusetts02114-
Research SiteBostonMassachusetts02215-
Research SiteBostonMassachusetts02215-
Research SiteDetroitMichigan48201-
Research SiteDetroitMichigan48202-
Research SiteRochesterMinnesota55905-
Research SiteAlbanyNew York12208-
Research SiteNew YorkNew York10016-
Research SiteNew YorkNew York10029-
Research SiteNew YorkNew York10065-
Research SiteNew YorkNew York10065-
Research SiteRochesterNew York14642-
Research SiteThe BronxNew York10467-
Research SiteChapel HillNorth Carolina27514-
Research SiteCharlotteNorth Carolina28204-
Research SiteWinston-SalemNorth Carolina27103-
Research SiteCincinnatiOhio45220-
Research SiteClevelandOhio44195-
Research SitePortlandOregon97239-
Research SiteCharlestonSouth Carolina29425-
Research SiteNashvilleTennessee37203-
Research SiteAustinTexas78704-
Research SiteDallasTexas75235-
Research SiteHoustonTexas77030-
Research SiteSalt Lake CityUtah84112-
Research SiteCharlottesvilleVirginia22908-
Research SiteGainesvilleVirginia20155-
Research SiteRichmondVirginia23298-
Research SiteSeattleWashington98104-
Research SiteMadisonWisconsin53792-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in Gilbert, AZ

By research site
Research Site· Gilbert, AZResearch Site· Phoenix, AZResearch Site· Tucson, AZResearch Site· La Jolla, CAResearch Site· Sacramento, CAResearch Site· Santa Monica, CA

Related Studies